Pharmaceutical Outcomes

Dr. Barnes’ research interests include implementation science focused on expanding the role of pharmacists in ambulatory settings, the use of population health management to improve the quality and cost of care provided in primary care settings, the sustainability of pharmacist-provided care in primary care settings, and methods to develop and support pharmacy practice preceptors. Dr. Barnes’ passion lies with mentoring the next generation of the profession to achieve their own personal goals and dreams.

Dr. Donneyong's passion is to improve health equity with respect to the effectiveness, safety and adherence to prescribed medications through research. His research interests include drug-drug interactions - adverse drug events precipitated by exposure to poly-pharmacy among older adults, especially racial/ethnic minorities; and medication adherence - the role of social determinants of health and patient-provider relationships in racial/ethnic disparities in medication adherence.

Dr. Nahata teaches in the pharmacotherapy and leadership courses, conducts clinical research to evaluate the effectiveness, safety, and usage of medications in the pediatric and adult populations, directs a postdoctoral pharmacotherapy research fellowship program, and serves on the committees of various national and international organizations.

Dr. Neidecker’s research interests include pharmacoeconomic analyses and health outcomes studies. Her scholarship also focuses on clinical research education and workforce development. She has experience in curriculum development and program evaluation, and she enjoys serving as a master's project advisor for students in the MS Health Systems Pharmacy Administration and Leadership program.

Dr. Phelps’ lab is involved in both pre-clinical and clinical development of numerous small molecule anti-cancer and immuno-modulatory agents under development. Their work aims to understand the mechanisms involved in the absorption, distribution, metabolism, and excretion (i.e. pharmacokinetics, PK) of these agents, and how both the PK and pharmacodynamic (PD) effects of these agents are altered by genetic differences (polymorphisms) among individuals (i.e. pharmacogenetics, PG).

Dr. Schmuhl’s primary professional interest is caring for patients with substance use disorders (SUD) and implementing harm reduction strategies both on and off campus. She actively works to educate healthcare professional students across Ohio to care for patients with SUD in a collaborative and effective way. Her research focuses on medication use for SUD, SUD education, harm reduction, and innovative pharmacy practice. Dr. Schmuhl is also passionate about mentoring undergraduates, professional students, and pharmacy residents and serving as a resource for students during their educational and professional journeys.

Dr. Sparreboom's research studies the contribution of solute carriers to chemotherapy-induced toxicity profiles, identifies chemical inhibitors of critical transporters, translates the findings to clinical trials in collaboration with scientists and oncologists, and ultimately improves the long-term outcome of patients with cancer by modulating the therapeutic window of widely-used chemotherapeutics. His research is currently focused on the development of transport modulators that could be used in conjunction with platinum-based drugs and tyrosine-kinase inhibitors, with emphasis on the development of innovative preclinical model systems.

Dr. Wei's area of research expertise is in geriatric pharmacoepidemiology, with specific focus areas on drug safety, drug effectiveness, and quality of medication prescribing in older adults, especially those with pain, neurodegenerative diseases (e.g., Alzheimer’s disease and related dementia [ADRD]), and nursing home stays.